581 related articles for article (PubMed ID: 15655719)
21. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
23. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
24. [Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].
Scheen AJ; Radermecker RP; Philips JC; Paquot N
Rev Med Suisse; 2007 Aug; 3(122):1884, 1886-8. PubMed ID: 17896662
[TBL] [Abstract][Full Text] [Related]
25. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
26. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
27. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
Triplitt C; Wright A; Chiquette E
Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
30. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
31. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
32. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
33. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
Göke B; Hoppe B; Konrad A; Schirra J
Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
[No Abstract] [Full Text] [Related]
34. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Baggio LL; Drucker DJ
Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Lindsay JR; Duffy NA; McKillop AM; Ardill J; O'Harte FP; Flatt PR; Bell PM
Diabet Med; 2005 May; 22(5):654-7. PubMed ID: 15842525
[TBL] [Abstract][Full Text] [Related]
36. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
37. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
Nielsen LL
Drug Discov Today; 2005 May; 10(10):703-10. PubMed ID: 15896683
[TBL] [Abstract][Full Text] [Related]
38. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
McIntosh CH; Demuth HU; Pospisilik JA; Pederson R
Regul Pept; 2005 Jun; 128(2):159-65. PubMed ID: 15780435
[TBL] [Abstract][Full Text] [Related]
39. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
40. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery.
Patriti A; Facchiano E; Sanna A; Gullà N; Donini A
Obes Surg; 2004; 14(6):840-8. PubMed ID: 15318993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
